Ramalingam Shares Notable Updates in NCCN Guidelines for EGFR+ NSCLC

Excerpt:

“Among the notable updates in the National Comprehensive Cancer Network’s (NCCN) recently released  treatment guidelines for non–small cell cancer (NSCLC) is the category 2A recommendation to give osimertinib (Tagrisso), a third-generation irreversible EGFR inhibitor designed to inhibit both EGFR-sensitizing and EGFR T790M-resistance mutations, in the first-line setting for patients whose disease is EGFR mutant, explains Suresh A. Ramalingam, MD.

“Osimertinib was also given a category 1 recommendation as a subsequent therapy after patients progressed on treatment with standard EGFR tyrosine kinase inhibitors (TKIs) erlotinib (Tarceva), gefitinib (Iressa), and afatinib (Gilotrif). The FDA granted a breakthrough therapy designation to a supplemental biologics license application for osimertinib as a frontline treatment for patients with metastatic EGFR-mutation–positive NSCLC in October 2017. The application was based on findings from the double-blind, phase III FLAURA trial, in which frontline osimertinib was associated with a 54% reduction in the risk of progression or death compared with standard therapy.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Guideline on Stage IV Non-Small-Cell Lung Cancer Therapy Updated

Excerpt:

“An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline clarifies the role of immunotherapy in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The update also provides new recommendations on the use of targeted therapies for patients with changes in tumor EGFRALK, and ROS1 genes.

” ‘Treatment for lung cancer has become increasingly more complex over the last several years. This guideline update provides oncologists the tools to choose therapies that are most likely to benefit their patients,’ said Nasser Hanna, MD, co-chair of the Expert Panel that developed the guideline update.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


New Guidelines Aim Treat Brain Tumors More Effectively

Excerpt:

“A University of Portsmouth academic has helped to develop European guidelines to treat brain tumours more effectively.

“Geoff Pilkington, Professor of Cellular and Molecular Neuro-oncology and one of the UK’s leading brain tumour specialists, was one of only three UK academics who devised the European Association for Neuro-Oncology (EANO) guidelines on the diagnosis and  of  with astrocytic and oligodendroglial gliomas, including glioblastomas.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Updates to NSCLC Guidelines Make Testing at Diagnosis, Resistance Essential

Excerpt:

“Updates to the National Comprehensive Cancer Network (NCCN) guidelines for the management of advanced non–small cell lung cancer (NSCLC) stress the importance of multiplexed biomarker testing at diagnosis to aid in the selection of appropriate first-line and subsequent lines of therapy, said presenters at the 2017 NCCN Annual Conference.

“The latest version of the guidelines recommends that PD-L1, in addition to molecular analysis, be employed as a biomarker to direct initial therapy, with ≥50% expression established as the threshold for a positive result. The PD-L1 test ‘decides whether a patient has enough of the marker to warrant initial immunotherapy,’ said presenter Gregory J. Riely, MD, PhD.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


NCCN Publishes Patient Education Resources for Gliomas—Its First in a Series on Brain Cancer

Excerpt:

“January 9, 2017) The National Comprehensive Cancer Network® (NCCN®) has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ sheets for Brain Cancer – Gliomas—the first in a series of patient education resources focused on Brain Cancer. Published by NCCN through support of the NCCN Foundation®, and, in part through funding from NCCN Foundation’s Team Pound the Pavement for Patients, these resources inform patients about their disease and the treatment options available to them.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Radiation from Medical Imaging May Increase Cancer Rates

Medical imaging techniques that use high doses of radiation, including computed tomography (CT) scans, play an important role in modern medicine, including cancer screening. However, these procedures may themselves increase the incidence of cancer. Radiation exposure from medical imaging in the U.S. has increased more than sixfold between the 1980s and 2006. Several studies have linked multiple CT scans to increased cancer risk. Moreover, there are no official guidelines on the correct radiation doses for different medical imaging techniques, meaning that doses at one hospital may be up to 50 times higher than at another. Clear standards are needed to ensure that high-radiation imaging techniques are only used when clearly medically necessary and that the lowest feasible radiation doses are employed.


Radiation from Medical Imaging May Increase Cancer Rates

Medical imaging techniques that use high doses of radiation, including computed tomography (CT) scans, play an important role in modern medicine, including cancer screening. However, these procedures may themselves increase the incidence of cancer. Radiation exposure from medical imaging in the U.S. has increased more than sixfold between the 1980s and 2006. Several studies have linked multiple CT scans to increased cancer risk. Moreover, there are no official guidelines on the correct radiation doses for different medical imaging techniques, meaning that doses at one hospital may be up to 50 times higher than at another. Clear standards are needed to ensure that high-radiation imaging techniques are only used when clearly medically necessary and that the lowest feasible radiation doses are employed.


Radiation from Medical Imaging May Increase Cancer Rates

Medical imaging techniques that use high doses of radiation, including computed tomography (CT) scans, play an important role in modern medicine, including cancer screening. However, these procedures may themselves increase the incidence of cancer. Radiation exposure from medical imaging in the U.S. has increased more than sixfold between the 1980s and 2006. Several studies have linked multiple CT scans to increased cancer risk. Moreover, there are no official guidelines on the correct radiation doses for different medical imaging techniques, meaning that doses at one hospital may be up to 50 times higher than at another. Clear standards are needed to ensure that high-radiation imaging techniques are only used when clearly medically necessary and that the lowest feasible radiation doses are employed.


Annual Lung Cancer Screening Recommended for High-Risk Individuals

The U.S. Preventive Services Task Force has published its final recommendations on lung cancer screening. The panel advises annual computed tomography (CT) scans for high-risk individuals (heavy smokers or former heavy smokers who have quit within the past 15 years) between 55 and 80 years of age. The recommendation is based on the results of a comprehensive review of the existing evidence and on modeling studies predicting the benefits and harms of different screening programs. Some experts have criticized the use of modeling data in developing the guidelines. Others consider practical concerns in implementing the recommendation, such as how to actually select those patients eligible and refer them to screening.